The global infectious disease diagnostics market is projected to reach USD 19.35 billion in 2022 from USD 14.73 billion in 2017, at CAGR of 5.6%. Growth in this market will largely be driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=116764589
The infectious disease diagnostics market is segmented on the basis of product & service, disease type, technology, end user, and region. Based on product & service, the market is broadly segmented into assays, kits & reagents; instruments; and services & software. The assays, kits, & reagents segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can primarily be attributed to the increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages.
On the basis of disease type, the market is broadly segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The HAIs diagnostics segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the rising burden of MRSA infections; the increasing number of new products launched in the market; and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assays, Xpert MRSA NxG, and ARIES C. difficile assays that are based on the PCR technology.
On the basis technology, the market is broadly segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and others. The DNA sequencing & NGS segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rapid growth in aging population, increasing awareness and acceptance of personalized medicine, technological advancements, and high sensitivity of DNA sequencing tests are driving the growth of this segment.
On the basis end user, the market is broadly segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic institutes, and other end users. The hospitals/clinical laboratories segment is projected to register the highest CAGR during the forecast period. The growth of this segment can primarily be attributed to the large number of diagnostic tests carried out in hospitals.
Geographically, Asia Pacific is expected to register the highest CAGR during the forecast period. The growth of this regional segment can be attributed to the growing GDPs and a significant rise in disposable income levels, increased healthcare spending by a larger population base, modernization of healthcare infrastructure, and rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas).
